UH3DA050322
Cooperative Agreement
Overview
Grant Description
Preclinical and clinical evaluation of the NMDA modulator NYX-783 for OUD.
Awardee
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Connecticut
United States
Geographic Scope
State-Wide
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased from $3,406,895 to $3,438,228.
Yale Univ was awarded
Preclinical and clinical evaluation of the NMDA modulator NYX-783 for OUD
Cooperative Agreement UH3DA050322
worth $3,438,228
from National Institute on Drug Abuse in September 2019 with work to be completed primarily in Connecticut United States.
The grant
has a duration of 6 years and
was awarded through assistance program 93.279 Drug Abuse and Addiction Research Programs.
The Cooperative Agreement was awarded through grant opportunity Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trials Optional).
Status
(Complete)
Last Modified 6/20/23
Period of Performance
9/30/19
Start Date
9/29/25
End Date
Funding Split
$3.4M
Federal Obligation
$0.0
Non-Federal Obligation
$3.4M
Total Obligated
Activity Timeline
Transaction History
Modifications to UH3DA050322
Additional Detail
Award ID FAIN
UH3DA050322
SAI Number
UH3DA050322-2456377782
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75N600 NIH NATIONAL INSITUTE ON DRUG ABUSE
Funding Office
75N600 NIH NATIONAL INSITUTE ON DRUG ABUSE
Awardee UEI
FL6GV84CKN57
Awardee CAGE
4B992
Performance District
03
Senators
Richard Blumenthal
Christopher Murphy
Christopher Murphy
Representative
Rosa DeLauro
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Institute on Drug Abuse, National Institutes of Health, Health and Human Services (075-0893) | Health research and training | Grants, subsidies, and contributions (41.0) | $3,438,228 | 100% |
Modified: 6/20/23